Originally published by our sister publication Clinical Oncology News
The FDA approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor (anti-VEGF) therapy; and, if RAS wild-type and medically appropriate, an anti–epidermal growth factor receptor (anti-EGFR) therapy.
Efficacy was evaluated in